LPCN Stock Forecast: Lipocine, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.50
0.00% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 39 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$16.6M
Ticker Nerd rank
39/ 100
Median analyst target
$5.00
Analysts covering
—
Revenue$190K−69.5% y/y
Operating income−$2.8M
Net income−$2.6M
Free cash flow−$3.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.3%
1M
−7.4%
YTD
−81.3%
1Y
−52.4%
From 52W high
−86.7%
From 52W low
+4.2%
$1
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Lipocine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
39/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
81
Volatility
65
Quality
49
Momentum
42
Issuance
30
Accruals
27
Growth
19
Value
16

Revisions (81): Analysts have, on balance, been raising their forecasts.

Value (16): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LPCN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LPCN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12Jan 26Apr 26Jul 26Oct 26LPCNHigh $6.00Median $5.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
21 Sept 2026HC Wainwright & Co.ReiteratesNeutral$4.00
6 Apr 2026HC Wainwright & Co.DowngradeNeutral—
21 Jan 2026HC Wainwright & Co.MaintainsBuy—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
20 Aug 2025HC Wainwright & Co.ReiteratesBuy—
27 June 2025HC Wainwright & Co.ReiteratesBuy—
10 June 2025HC Wainwright & Co.ReiteratesBuy—
29 May 2025HC Wainwright & Co.AssumesBuy$8.00
24 Sept 2024Alliance Global PartnersInitiatesBuy$10
27 July 2023Cantor FitzgeraldReiteratesOverweight—
26 Aug 2021HC Wainwright & Co.MaintainsBuy$2.50 → $3.50
24 June 2021Cantor FitzgeraldInitiatesOverweight—
27 May 2021HC Wainwright & Co.MaintainsBuy$3.00 → $2.50
10 Dec 2020Ladenburg ThalmannUpgradeBuy—
27 May 2020HC Wainwright & Co.MaintainsBuy$2.00 → $3.00
29 Mar 2018Seaport GlobalInitiatesBuy—
27 Feb 2018Empire Asset ManagementUpgradeBuy—
11 Jan 2018Canaccord GenuityDowngradeHold—
7 Oct 2016H.C. WainwrightInitiatesBuy—
7 Oct 2016HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

LPCN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LPCN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Lipocine, Inc. returned −52.4% against +6.9% for the S&P 500, dividends included.

LPCN vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200250300350Jan 26Apr 26Jul 26Oct 26LPCNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LPCN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
4.2×

Cheaper than 25% of US stocks

Price / book
0.6×

Cheaper than 84% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−52.9%

Higher than 21% of US stocks

Return on assets
−32.1%

Higher than 13% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lipocine, Inc. has a market value of $16.6M.

  • Revenue in the twelve months to 30 June 2026: $1.6M. The latest quarter shrank 69.5% year on year.

  • Net income over the same four quarters: −$11.9M, a −755.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$11.2M.

  • Shares outstanding: 8.2M.

  • Lipocine, Inc. employs 14 people — $112K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

LPCN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LPCNLipocine, Inc.$16.6M39
ATOSAtossa Therapeutics, Inc.$15.9M22
PBMPsyence Biomedical Ltd.$15.8M4
KTTAPasithea Therapeutics Corp.$17.6M13
CELUCelularity, Inc.$15.0M29
MRKRMarker Therapeutics, Inc.$18.2M76
CNTXContext Therapeutics, Inc.$14.7M38

Take a look at LPCN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Lipocine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LPCN

How does Ticker Nerd's model rank LPCN?

As at 21 Nov 2026, Lipocine, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (81 of 100).

What is the LPCN stock forecast for 2030?

No analyst covering Lipocine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LPCN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $6 over the next 12 months.

How has LPCN stock performed over the past year?

Lipocine, Inc. returned -52.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lipocine, Inc. do?

Lipocine Inc. is a biopharmaceutical company focused on developing oral drug delivery products that improve the administration of therapies that are traditionally difficult to formulate. The company’s current portfolio includes TLANDO, an oral testosterone replacement therapy for men with low testosterone, and LPCN 1154 (BRLIZIO™), an oral neurosteroid under development for postpartum depression.

Company

About Lipocine, Inc.

Lipocine Inc. is a biopharmaceutical company focused on developing oral drug delivery products that improve the administration of therapies that are traditionally difficult to formulate. The company’s current portfolio includes TLANDO, an oral testosterone replacement therapy for men with low testosterone, and LPCN 1154 (BRLIZIO™), an oral neurosteroid under development for postpartum depression. Lipocine also advances additional product candidates across hormone-related, liver, and women’s health areas, using its proprietary delivery technology platform to support convenient oral dosing and differentiated therapeutic profiles. Based in Salt Lake City, Utah, Lipocine operates in the specialty pharmaceuticals and clinical-stage biotechnology markets, with its work centered on translating complex drug molecules into patient-friendly oral treatments.

CEO Dr. Mahesh V. Patel Ph.D. · 14 employees · United States · https://www.lipocine.com